Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases

Journal of Clinical Densitometry

Volumn 11, Issue 2, 2008, Pages 325-338

  Delmas, Pierre D ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

Bone mineral density; denosumab; monoclonal antibody; osteoporosis; RANK ligand

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ESTROGEN; GESTAGEN; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

BONE DENSITY; BONE NECROSIS; BONE REMODELING; CLINICAL TRIAL; DRUG DOSE ESCALATION; ESOPHAGUS DISEASE; HUMAN; METABOLIC BONE DISEASE; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RANK LIGAND;

EID: 42749092176     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2008.02.002     Document Type: Review

References (151)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement Online. March 27-29, 2000 17:1-36.
2. Garnero P., and Delmas P.D. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4 (2004) 50-63
3. U.S. Department of Health and Human Services. Chapter 2: The basics of bone health and disease. Bone Health and Osteoporosis: A Report of the Surgeon General (2004), U.S. Department of Health and Human Services, Office of the Surgeon General
4. U.S. Department of Health and Human Services. Chapter 5: The burden of bone disease. Bone Health and Osteoporosis: A Report of the Surgeon General (2004), U.S. Department of Health and Human Services, Office of the Surgeon General
5. Who are candidates for prevention and treatment for osteoporosis?. Osteoporos Int 7 (1997) 1-6
6. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation (2002), National Osteoporosis Foundation, Washington, DC
7. Randell A., Sambrook P.N., Nguyen T.V., et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 5 (1995) 427-432
8. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17 (2006) 1726-1733
9. Jordan K.M., and Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 16 (2002) 795-806
10. Chrischilles E., Shireman T., and Wallace R. Costs and health effects of osteoporotic fractures. Bone 15 (1994) 377-386
11. Melton III L.J., Thamer M., Ray N.F., et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12 (1997) 16-23
12. Cummings S.R., Black D.M., and Rubin S.M. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149 (1989) 2445-2448
13. Kanis J.A., Delmas P., Burckhardt P., Cooper C., et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7 (1997) 390-406
14. Tosteson A.N. Economic impact of fractures. In: Orwoll E.S. (Ed). Osteoporosis in Men: The Effects of Gender on Skeletal Health (1999), Academic Press 15-27
15. Braithwaite R.S., Col N.F., and Wong J.B. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51 (2003) 364-370
16. Albright F., Smith P.H., and Richardson A.M. Postmenopausal osteoporosis. JAMA 116 (1941) 2465-2474
17. Recker R.R., Kimmel D.B., Parfitt A.M., et al. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3 (1988) 133-144
18. Garnero P., Sornay-Rendu E., Claustrat B., and Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15 (2000) 1526-1536
19. Garcia Palacios V., Robinson L.J., Borysenko C.W., et al. Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 Cells by estrogen and phytoestrogens. J Biol Chem 280 (2005) 13720-13727
20. Nakamura T., Imai Y., Matsumoto T., et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130 (2007) 811-823
21. Syed F., and Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 328 (2005) 688-696
22. Krassas G.E., and Papadopoulou P. Oestrogen action on bone cells. J Musculoskelet Neuronal Interact 2 (2001) 143-151
23. Garnero P., Sornay-Rendu E., Chapuy M.C., and Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11 (1996) 337-349
24. Compston J.E. Sex steroids and bone. Physiol Rev 81 (2001) 419-447
25. Seeman E., and Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354 (2006) 2250-2261
26. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
27. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
28. Min H., Morony S., Sarosi I., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 (2000) 463-474
29. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
30. Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
31. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95 (1998) 3597-3602
32. Burgess T.L., Qian Y., Kaufman S., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145 (1999) 527-538
33. Fuller K., Wong B., Fox S., et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188 (1998) 997-1001
34. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96 (1999) 3540-3545
35. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
36. Li J., Sarosi I., Yan X.Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97 (2000) 1566-1571
37. Kong Y.Y., Feige U., Sarosi I., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
38. Silvestrini G., Ballanti P., Patacchioli F., et al. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol 36 (2005) 59-67
39. Takami M., Cho E.S., Lee S.Y., Kamijo R., et al. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 579 (2005) 832-838
40. Lacey D.L., Tan H.L., Lu J., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157 (2000) 435-448
41. Eghbali-Fatourechi G., Khosla S., Sanyal A., et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111 (2003) 1221-1230
42. Hofbauer L.C., Khosla S., Dunstan C.R., et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 (1999) 4367-4370
43. Khosla S., Atkinson E.J., Dunstan C.R., and O'Fallon W.M. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87 (2002) 1550-1554
44. Saika M., Inoue D., Kido S., and Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 142 (2001) 2205-2212
45. Viereck V., Grundker C., Blaschke S., et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 88 (2003) 4206-4213
46. Shevde N.K., Bendixen A.C., Dienger K.M., and Pike J.W. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A 97 (2000) 7829-7834
47. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
48. Delmas P.D. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11 Suppl 6 (2000) S66-S76
49. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85 (2000) 231-236
50. Delmas P.D. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?. Bone 27 (2000) 1-3
51. Eastell R., Barton I., Hannon R.A., et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1056
52. Bauer D.C., Black D.M., Garnero P., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19 (2004) 1250-1258
53. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 276 (1996) 1389-1396
54. Pors Nielsen S., Barenholdt O., Hermansen F., and Munk-Jensen N. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol 101 (1994) 319-324
55. Prestwood K.M., Kenny A.M., Unson C., and Kulldorff M. The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 85 (2000) 4462-4469
56. Recker R.R., Davies K.M., Dowd R.M., and Heaney R.P. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 130 (1999) 897-904
57. Kiel D.P., Felson D.T., Anderson J.J., et al. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 317 (1987) 1169-1174
58. Maxim P., Ettinger B., and Spitalny G.M. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 5 (1995) 23-29
59. Paganini-Hill A., Ross R.K., Gerkins V.R., et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 95 (1981) 28-31
60. Torgerson D.J., and Bell-Syer S.E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285 (2001) 2891-2897
61. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
62. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
63. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2006) 125-137
64. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 (2001) 125-134
65. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (1999) 2189-2197
66. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. 4th ed. (2000), Academic Press, San Diego
67. U.S. Department of Health and Human Services. Chapter 9: Prevention and treatment for those who have bone disease. Bone Health and Osteoporosis: A Report of the Surgeon General (2004), U.S. Department of Health and Human Services, Office of the Surgeon General
68. Hosking D., Chilvers C.E., Christiansen C., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 338 (1998) 485-492
69. McClung M., Clemmesen B., Daifotis A., et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 128 (1998) 253-261
70. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
71. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85 (2000) 4118-4124
72. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
73. Pols H.A., Felsenberg D., Hanley D.A., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9 (1999) 461-468
74. Mortensen L., Charles P., Bekker P.J., et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83 (1998) 396-402
75. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
76. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
77. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
78. Chesnut I.C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
79. Delmas P.D., Recker R.R., Chesnut III C.H., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15 (2004) 792-798
80. Miller P.D., McClung M.R., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322
81. Adami S., Felsenberg D., Christiansen C., et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34 (2004) 881-889
82. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 (2002) 653-661
83. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
84. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357 (2007) 1799-1809
85. de Groen P.C., Lubbe D.F., Hirsch L.J., et al. Esophagitis associated with the use of alendronate. N Engl J Med 335 (1996) 1016-1021
86. Dunn C.J., and Goa K.L. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 61 (2001) 685-712
87. Sharpe M., Noble S., and Spencer C.M. Alendronate: an update of its use in osteoporosis. Drugs 61 (2001) 999-1039
88. Bilezikian J.P. Osteonecrosis of the jaw-do bisphosphonates pose a risk?. N Engl J Med 355 (2006) 2278-2281
89. Woo S.B., Hellstein J.W., and Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
90. Lenz J.H., Steiner-Krammer B., Schmidt W., et al. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J Craniomaxillofac Surg 33 (2005) 395-403
91. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
92. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
93. Sexton P.M., Findlay D.M., and Martin T.J. Calcitonin. Curr Med Chem 6 (1999) 1067-1093
94. Chesnut III C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109 (2000) 267-276
95. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
96. Meunier P.J., Slosman D.O., Delmas P.D., et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87 (2002) 2060-2066
97. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90 (2005) 2816-2822
98. Baron R., and Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 450 (2002) 11-17
99. Canalis E., Hott M., Deloffre P., et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18 (1996) 517-523
100. Takahashi N., Sasaki T., Tsouderos Y., and Suda T. S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18 (2003) 1082-1087
101. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
102. Seeman E., and Delmas P.D. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 12 (2001) 281-283
103. Dempster D.W., Cosman F., Kurland E.S., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16 (2001) 1846-1853
104. Hodsman A.B., Bauer D.C., Dempster D.W., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26 (2005) 688-703
105. Solomon D.H., Avorn J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med 165 (2005) 2414-2419
106. Weycker D., Macarios D., Edelsberg J., and Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17 (2006) 1645-1652
107. McCombs J.S., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
108. Caro J.J., Ishak K.J., Huybrechts K.F., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
109. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
110. Capparelli C., Morony S., Warmington K., et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18 (2003) 852-858
111. Martin S.W., Sommers J.S., Watson A.M., et al. The pharmacokinetics and pharmacodynamics of OPG following single dose administration in cynomolgus monkeys. J. Bone Miner Res 14 (1999) S523
112. Ross A.B., Bateman T.A., Kostenuik P.J., et al. The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 12 (2001) 583-588
113. Li X., Asuncion F., Ominsky M., et al. RANKL inhibition with OPG preserves bone density and trabecular architecture in ovariectomized rats. J Bone Miner Res 21 (2006) S304
114. Kostenuik P.J., Capparelli C., Morony S., et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142 (2001) 4295-4304
115. Bekker P.J., Holloway D., Nakanishi A., et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16 (2001) 348-360
116. Atkinson J.E., Cranmer P., Mohr S., et al. Bone mineral density is increased following monthly administration of AMG 162 in cynomologus monkeys. J Bone Miner Res 18 (2003) S96
117. Peterson MC, Stouch BJ, Chen D, et al. AMG 162, a fully human monoclonal antibody against receptor activator of NF-kappa B ligand (RANKL), rapidly and profoundly suppresses bone resorption in cynomolgus monkey IBMS/JSBMR Joint Meeting. Osaka, Japan; 2003.
118. Ominsky M., Schroeder J., Smith S.Y., et al. Denosumab (AMG 162, a fully human RANKL antibody) increases cortical and cancellous bone mass and density in aged ovariectomized cynomologus monkeys. J Bone Miner Res 21 (2006) S72
119. Ominsky M.S., Schroeder J., Smith S.Y., et al. Denosumab (AMG 162), a fully human RANKL antibody, improves cortical and cancellous bone mass and bone strength in ovariectomized cynomolgus monkeys. J Bone Miner Res 22 Suppl 1 (2007) S23
120. Peterson M.C., Stouch B.J., Chen D., et al. AMG 162 maintains serum concentration for up to 9 months following a single subcutaneous dose in healthy postmenopausal women. J Bone Miner Res 18 (2003) S166
121. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19 (2004) 1059-1066
122. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821-831
123. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22 (2007) 1832-1841
124. Miller P., Bolognese M., Lewiecki E.M., et al. Effect of denosumab on bone mineral density and bone turnover markers: 48-month results. J Bone Miner Res 22 Suppl 1 (2007) S58 Abstract 1205 and oral presentation
125. Sasaki N., Kusano E., Ando Y., et al. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 16 (2001) 479-482
126. von Tirpitz C., Epp S., Klaus J., et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 15 (2003) 1165-1170
127. Locklin R.M., Khosla S., Turner R.T., and Riggs B.L. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 89 (2003) 180-190
128. Hofbauer L.C., Kuhne C.A., and Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4 (2004) 268-275
129. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004) 490-495
130. Coleman R.E. Hormone- and chemotherapy-induced bone loss in breast cancer. Oncology (Williston Park) 18 (2004) 16-20
131. Stoch S.A., Parker R.A., Chen L., et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86 (2001) 2787-2791
132. Theriault R.L. Pathophysiology and implications of cancer treatment-induced bone loss. Oncology (Huntingt) 18 (2004) 11-15
133. Hofbauer L.C., Shui C., Riggs B.L., et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280 (2001) 334-339
134. Rubin J., Murphy T., Nanes M.S., and Fan X. Mechanical strain inhibits expression of osteoclast differentiation factor by murine stromal cells. Am J Physiol Cell Physiol 278 (2000) C1126-C1132
135. Kitazawa S., and Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198 (2002) 228-236
136. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2 (2002) 584-593
137. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 (2004) 1655-1664
138. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 (1999) 4382-4389
139. Bateman T.A., Dunstan C.R., Lacey D.L., et al. Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. J Orthop Res 19 (2001) 518-523
140. Mochizuki S., Fujise N., Higashio K., and Tsuda E. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. J Bone Miner Metab 20 (2002) 14-20
141. Morony S., Lu J., Capparelli C., et al. Osteoprotegerin (OPG) prevents bone loss in a rat model of glucocorticoid-induced osteopenia. J Bone Miner Res 16 (2001) S148
142. Morony S., Capparelli C., Sarosi I., et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61 (2001) 4432-4436
143. Zhang J., Dai J., Yao Z., et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63 (2003) 7883-7890
144. Vanderkerken K., De Leenheer E., Shipman C., et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 63 (2003) 287-289
145. Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12 (2006) 1221-1228
146. Suarez T., Fizazi K., Rahim Y., et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. J Clin Oncol 24 (2006) 8562
147. Lipton A., Steger G.G., Figueroa J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25 (2007) 4431-4437
148. Cohen S., Valen P., Ritchlin C., et al. RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: month 6 MRI results. [abstract]. Arthritis Rheum 54 (2006) Abstract 2120
149. van der Heijde D., Cohen S.B., Sharp J.T., et al. The RANKL inhibitor denosumab reduces progression of the Total Sharp Score and bone erosions in patients with rheumatoid arthritis: x-ray results at 12 months. Ann Rheum Dis 66 Suppl II (2007) 89
150. Lane N., Iannini M., Atkins C., et al. RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis. Arthritis Rheum 54 Suppl 9 (2006) S225
151. Dore R.K., Hurd E., Palmer W., et al. Denosumab increases bone mineral density in patients with rheumatoid arthritis: 12-month results. J Bone Miner Res 22 Suppl 1 (2007) S59